ARM Shorts Jump as Sector Sells Off Hard
Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish
ARM shares fell nearly 10% on Friday alone, closing at $205.97. The one-month loss now stands at 30%. Among its closest Nasdaq peers, AMD dropped 10.9% on the day, LSCC fell 9.7%, and MRVL was down 10%. ARM's weekly decline of 2.1% was steeper than the peer median of 0.2%, though Friday's tape showed the whole semiconductor complex under heavy pressure.
Short interest rose sharply into that weakness. Borrowed shares climbed roughly 9.7% over the past week to around 17.9 million, a move that ORTEX data shows running 1.6 standard deviations above ARM's typical weekly change. The build is meaningful in absolute terms: from mid-September through mid-October, short interest held in a range of 15.2 to 16.6 million shares, then stepped up cleanly from October 23 onward. That two-stage move suggests the fresh positioning arrived before Friday's sell-off, not because of it. Borrow cost has edged higher alongside, rising 22% on the week to 0.46%, though it remains low in absolute terms. Availability is ample at roughly 586%, meaning there is no structural squeeze pressure; plenty of lending supply exists relative to current short demand.
Options sentiment has leaned defensive for much of October. The put/call ratio closed Friday at 1.36, close to its 20-day mean of 1.35 and well off the 52-week high of 1.45 reached on October 19. The ratio has been running persistently above 1.0 since late September, a sustained rather than sudden shift toward downside hedging. The ORTEX short score sits at 55, mid-range, consistent with the broader picture of rising short interest against loose borrow conditions.
The Street is cautious but not outright negative. The consensus sits at hold, with 13 holds and one underperform in the active count. The most recent analyst actions are from late July, when Morgan Stanley nudged its Equal-Weight target up to $212 while most other firms lowered theirs. UBS cut from $360 to $320 while keeping Buy; TD Cowen and RBC trimmed targets sharply from $475 to $350 and $340 respectively. The pattern is a downward drift in price targets from elevated levels, rather than a change in directional conviction. Morgan Stanley's $212 target is now the closest to the current $205.97 price, sitting barely above it. The bull case centres on 20% royalty revenue growth through 2031 on Armv9 adoption, plus early-stage CPU revenue that could reach $15 billion by FY2031. The bear case points to SoftBank's 86% ownership concentration, design-services revenue shrinking as a proportion of the total, and the risk that raising royalty rates alienates the customer base that makes those projections possible.
Insider activity over the past 90 days adds a one-directional note. The CFO, Jason Child, sold 20,800 shares in two tranches in August and September, realising around $5.8 million. Both were executed under a pre-arranged 10b5-1 plan, which reduces their informational value as signals. No open-market purchases appear in the record. Wikipedia attention for ARM hit a z-score of 2.0 against its own 90-day history as of October 27, a notable spike in retail interest that arrived just before Friday's sharp drop.
The level to watch is the short interest count itself. The build from 15.2 million to 17.9 million shares over five weeks has been steady rather than parabolic. Whether that pace continues or the fresh shorts cover into the next earnings print on November 4 will define what the positioning data says about conviction on either side.
Stocks in this article
See the live data behind this article on ORTEX.
Open ARM on ORTEX →How this article was generated
- Generated
- 31 Oct 2026, 20:59
- Data as of
- 31 Oct 2026, 20:58
- Prompt version
- v1.0
- Data sources
- Short interestCost to borrowUtilizationOptions flowEarningsAnalyst consensusInstitutional positioningORTEX Alpha signalsRecent ORTEX notesAlt Data
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.